Suboptimally cytoreduced advanced ovarian cancer Cancer
Conditions
Interventions
All patients underwent primary cytoreductive surgery, including total hysterectomy, bilateral adnexectomy, and omentectomy, with peritoneal biopsies obtained at laparotomy. No extended surgery (bowel
Sponsors
Moscow Regional Oncological Dispensary
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 18 years to 75 years 2. Histologically confirmed advanced epithelial ovarian cancer 3. Presence of peritoneal metastases 4. Suboptimal primary cytoreductive surgery with residual disease greater than 1 cm 5. No extra-peritoneal metastases 6. No malignant pleural effusion 7. No parenchymal organ metastases 8. Eastern Cooperative Oncology Group (ECOG) performance status not equal to 4 9. No synchronous malignancies 10. No receipt of neoadjuvant chemotherapy
Exclusion criteria
Exclusion criteria: 1. Severe concomitant somatic, mental, and other pathology in a stage of exacerbation or decompensation 2. Cachexia with body mass index less than or equal to 16.0 kg/m² 3. Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4 4. Pregnancy and lactation 5. Presence of extra abdominal metastases 6. Presence of a tumour of another localisation, meaning a primary multiple synchronous or metachronous process, except for metachronous neoplasms detected 2 or more years ago and in remission at the time of inclusion 7. Severe adhesions in the abdominal cavity when it is not possible to separate the adhesional conglomerate and achieve complete haemostasis, including cases where an adequate laparoscopic approach cannot be performed 8. Any other clinical condition that, in the opinion of the researcher, may interfere with the safe implementation of the protocol 9. Patient refusal to continue participating in the study at any stage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival measured using patient records at the data cutoff (15.1.2025);Overall Survival measured using patient records at the data cutoff (15.1.2025) | — |
Countries
Russian Federation
Contacts
Public ContactAlexey Dzasokhov
Outcome results
None listed